Safety evaluation of pharmacological interventions: a review of recent published meta-analysis
Safety evaluation of pharmacological interventions: a review of recent published meta-analysis
Alves C, Macedo AF, Craveiro N, Batel Marques F
2011
Increased severity of adverse drug reactions reported from hospitals.
Increased severity of adverse drug reactions reported from hospitals.
Batel Marques FJ, Alves C, Craveiro N, Fontes-Ribeiro C, Macedo AF
Pharmacoepidemiol Drug Safe 2011;20:S330
2011
Hypersensitivity syndrome due to drug exposure – ten years case review.
Hypersensitivity syndrome due to drug exposure – ten years case review.
Craveiro N, Alves C, Fontes Ribeiro C,Batel Marques FJ
Pharmacoepidemiol Drug Saf 2011;20:S332-S333
2011
Omissão de fármacos modificadores do risco cardiovascular em idosos admitidos numa Unidade de Acidentes Vasculares Cerebrais.
Omissão de fármacos modificadores do risco cardiovascular em idosos admitidos numa Unidade de Acidentes Vasculares Cerebrais.
Borges EP, Macedo AF
Rev Port Clin Geral 2011;27:140-150
2011
Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.
Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.
Alves C, Macedo AF, Batel Marques F
Pharmacotherapy 2011;31(10):357e
2011
Fecundação in vitro em Portugal: um estudo de custo-efectividade.
Fecundação in vitro em Portugal: um estudo de custo-efectividade.
Silva V, Pita Barros P, Lourenço O, Batel-Marques F.
Rev Port Farmacoter 2011;3:139-153
2011
Política do Medicamento.
Política do Medicamento.
Batel Marques F
Rev Port Farmacoter 2011;3:165-168
2011
Prescrição de Medicamentos Off-Label.
Prescrição de Medicamentos Off-Label.
Batel Marques F, Cunha Vaz J
Rev Port Farmacoter 2011;3:169-171
2011
Data sources on drug safety evaluation: a review of recent published meta-analysis.
Data sources on drug safety evaluation: a review of recent published meta-analysis.
Alves C, Batel Marques F, Macedo AF
Pharmacoepidemiol Drug Saf 2012;21(1):21-33
2011
Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.
Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.
Alves C, Batel-Marques F, Macedo AF.
J Cardiovasc Pharmacol Therap 2011 1 Dec. doi: 10.1177/1074248411427402
2011
